NASDAQ:ENGN - Nasdaq - CA29286M1059 - Common Stock - Currency: USD
4.2
+0.29 (+7.42%)
The current stock price of ENGN is 4.2 USD. In the past month the price increased by 5%. In the past year, price decreased by -67.34%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18 | 327.00B | ||
AMGN | AMGEN INC | 13.25 | 147.86B | ||
GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
NTRA | NATERA INC | N/A | 21.01B | ||
BIIB | BIOGEN INC | 8.25 | 19.13B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 56 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The firm is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
ENGENE HOLDINGS INC
4868 Rue Levy, Suite 220
Saint-Laurent QUEBEC CA
Employees: 32
Phone: 15143324888
The current stock price of ENGN is 4.2 USD. The price increased by 7.42% in the last trading session.
The exchange symbol of ENGENE HOLDINGS INC is ENGN and it is listed on the Nasdaq exchange.
ENGN stock is listed on the Nasdaq exchange.
17 analysts have analysed ENGN and the average price target is 24.48 USD. This implies a price increase of 482.86% is expected in the next year compared to the current price of 4.2. Check the ENGENE HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ENGENE HOLDINGS INC (ENGN) has a market capitalization of 214.12M USD. This makes ENGN a Micro Cap stock.
ENGENE HOLDINGS INC (ENGN) currently has 32 employees.
ENGENE HOLDINGS INC (ENGN) has a resistance level at 4.2. Check the full technical report for a detailed analysis of ENGN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ENGN does not pay a dividend.
ENGENE HOLDINGS INC (ENGN) will report earnings on 2025-06-11.
ENGENE HOLDINGS INC (ENGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.52).
ChartMill assigns a technical rating of 1 / 10 to ENGN. When comparing the yearly performance of all stocks, ENGN is a bad performer in the overall market: 94.61% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ENGN. While ENGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ENGN reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS decreased by -118.2% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.15% | ||
ROE | -27.62% | ||
Debt/Equity | 0.09 |
ChartMill assigns a Buy % Consensus number of 85% to ENGN. The Buy consensus is the average rating of analysts ratings from 17 analysts.